BFS
CPRX

Bare Financial Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Bare Financial Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.95K Buy
200
+174
+669% +$4.14K ﹤0.01% 650
2025
Q4 		$607 Hold
26
– – ﹤0.01% 1298
2025
Q3 		$512 Buy
+26
New +$535 ﹤0.01% 1275

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bare Financial Services's CPRX Position: Q1 2026 in Review

Bare Financial Services increased its Catalyst Pharmaceutical (CPRX) stake by 669% in Q1 2026, buying an estimated $4.14K and bringing the position to 200 shares worth $4.95K. The position accounts for ﹤0.01% of the portfolio, ranked #650.

Bare Financial Services first reported a position in CPRX in Q3 2025 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Bare Financial Services held 200 shares of Catalyst Pharmaceutical worth $4.95K as of Q1 2026.
  • Bare Financial Services bought 174 Catalyst Pharmaceutical shares in Q1 2026, an estimated $4.14K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Bare Financial Services's portfolio in Q1 2026, its #650 holding.
  • Bare Financial Services first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 3 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Bare Financial Services's 13F filing for Q1 2026, filed 14 May 2026.